Brief Report: Updated Efficacy and Safety Data From an Integrated Analysis of Entrectinib in Locally Advanced/Metastatic ROS1 Fusion-Positive Non–Small-Cell Lung Cancer

医学 ROS1型 内科学 肺癌 肿瘤科 不利影响 人口 癌症 临床试验 胃肠病学 腺癌 环境卫生
作者
Yun Fan,Alexander Drilon,Chao‐Hua Chiu,Herbert H. Loong,Salvatore Siena,Maciej Krzakowski,Rafał Dziadziuszko,Harald Zeuner,Cloris Xue,Matthew Krebs
出处
期刊:Clinical Lung Cancer [Elsevier BV]
卷期号:25 (2): e81-e86.e4 被引量:1
标识
DOI:10.1016/j.cllc.2023.12.001
摘要

•Genetic alterations in ROS1 can lead to the expression of oncogenic fusion proteins in multiple tumor types, including in 1% to 2% of non–small-cell lung cancer (NSCLC) cases. Approximately 40% of patients with ROS1 fusion-positive NSCLC have baseline central nervous system (CNS) metastases, indicating the need for a treatment with CNS activity. Entrectinib, a potent ROS1 tyrosine kinase inhibitor with activity in the CNS, has previously demonstrated overall and intracranial efficacy, and a manageable safety profile, in patients with ROS1 fusion-positive NSCLC.•In this updated analysis with 4 additional patients and longer follow-up, the objective response rate (ORR) in the efficacy-evaluable population (N = 172) was 67%; median duration of response (DoR) was 20.4 months, and median progression-free survival was 16.8 months. In 51 patients with baseline CNS metastases, intracranial ORR was 49% and median intracranial DoR was 12.9 months. In a subgroup analysis in patients who had not received any prior systemic therapy in the metastatic setting, ORR was similar to that in the efficacy-evaluable population, but median DoR was numerically longer at 35.6 months. Most treatment-related adverse events were grade 1 to 2 and nonserious.•These data reinforce previous findings on the use of entrectinib for the treatment of patients with ROS1 fusion-positive NSCLC, and support current guidelines that recommend entrectinib as a first-line treatment option for these patients, including those with baseline CNS metastases. •Genetic alterations in ROS1 can lead to the expression of oncogenic fusion proteins in multiple tumor types, including in 1% to 2% of non–small-cell lung cancer (NSCLC) cases. Approximately 40% of patients with ROS1 fusion-positive NSCLC have baseline central nervous system (CNS) metastases, indicating the need for a treatment with CNS activity. Entrectinib, a potent ROS1 tyrosine kinase inhibitor with activity in the CNS, has previously demonstrated overall and intracranial efficacy, and a manageable safety profile, in patients with ROS1 fusion-positive NSCLC.•In this updated analysis with 4 additional patients and longer follow-up, the objective response rate (ORR) in the efficacy-evaluable population (N = 172) was 67%; median duration of response (DoR) was 20.4 months, and median progression-free survival was 16.8 months. In 51 patients with baseline CNS metastases, intracranial ORR was 49% and median intracranial DoR was 12.9 months. In a subgroup analysis in patients who had not received any prior systemic therapy in the metastatic setting, ORR was similar to that in the efficacy-evaluable population, but median DoR was numerically longer at 35.6 months. Most treatment-related adverse events were grade 1 to 2 and nonserious.•These data reinforce previous findings on the use of entrectinib for the treatment of patients with ROS1 fusion-positive NSCLC, and support current guidelines that recommend entrectinib as a first-line treatment option for these patients, including those with baseline CNS metastases.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
芹菜自愿内卷完成签到,获得积分10
刚刚
zokor完成签到 ,获得积分0
3秒前
努力退休小博士完成签到 ,获得积分10
4秒前
橙子完成签到,获得积分10
5秒前
陈补天完成签到 ,获得积分10
6秒前
CipherSage应助慧灰huihui采纳,获得10
7秒前
乐观健柏完成签到,获得积分10
8秒前
10秒前
CodeCraft应助大橙子采纳,获得10
10秒前
量子星尘发布了新的文献求助10
11秒前
jeeya完成签到,获得积分10
12秒前
14秒前
科目三应助科研通管家采纳,获得10
14秒前
科目三应助科研通管家采纳,获得10
14秒前
伦语发布了新的文献求助10
14秒前
顾矜应助科研通管家采纳,获得10
14秒前
xuzj应助科研通管家采纳,获得10
14秒前
xuzj应助科研通管家采纳,获得10
14秒前
14秒前
NexusExplorer应助科研通管家采纳,获得10
14秒前
14秒前
14秒前
丘比特应助科研通管家采纳,获得10
15秒前
yull完成签到,获得积分10
15秒前
小巧书雪完成签到,获得积分10
18秒前
大大怪将军完成签到,获得积分10
19秒前
哈哈哈完成签到 ,获得积分0
19秒前
小怪完成签到,获得积分10
20秒前
爱吃泡芙完成签到,获得积分10
21秒前
白桃战士完成签到,获得积分10
22秒前
24秒前
qingchenwuhou完成签到 ,获得积分10
24秒前
XXX完成签到,获得积分10
25秒前
锡嘻完成签到 ,获得积分10
25秒前
26秒前
彗星入梦完成签到 ,获得积分10
26秒前
恋恋青葡萄完成签到,获得积分10
26秒前
隐形万言完成签到,获得积分10
28秒前
Time完成签到,获得积分10
28秒前
土木研学僧完成签到,获得积分10
29秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038201
求助须知:如何正确求助?哪些是违规求助? 3575940
关于积分的说明 11373987
捐赠科研通 3305747
什么是DOI,文献DOI怎么找? 1819274
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022